the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

COVID-19 cases up 14.8% last week – MOH

PUTRAJAYA: The number of COVID-19 cases increased by 14.8% to 1,230 cases in the 20th Epidemiological Week (EW 20/2024) from May 12 to 18, according to the Health Ministry (MOH).

In a statement today, MOH said no COVID-19-related fatalities have been recorded since April 25.

Regarding the admission of COVID-19 patients to healthcare facilities during the week, it said the occupancy rate of non-critical beds increased slightly from 0.08% to 0.10%, while the ICU bed occupancy rate decreased from 0.17% to 0.04%.

“MOH continuously monitors the COVID-19 situation in Malaysia and globally. Following the recent wave in Singapore, which saw a two-fold increase in cases in the week of May 5 to 11, the ministry has heightened preparedness measures to address potential increase in cases in Malaysia,” it said.

According to MOH, the variant currently circulating in Malaysia remained the Omicron variant and its subvariants.

It said that there has been one case each of KP.2.1 and KP.1.1 reported since March 2024, both are part of the Omicron family.

“Specifically, they are sublineages of JN.1.11.1. On May 3, the World Health Organisation listed KP.2 as a Currently Circulating Variant Under Monitoring (VUM). However, this variant has not led to severe infections in those affected,” it added.

ALSO READ: COVID-19: MOH closely tracking recent wave in Singapore – Dzulkefly

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings